Clinical Trial Results: Cytokinetics announced positive results from the SEQUOIA-HCM trial, showing that aficamten significantly improves cardiac structure, function, and patient symptoms in individuals with obstructive hypertrophic cardiomyopathy (HCM), alongside favorable changes in biomarkers.
Upcoming Conference: The company will host a conference call on September 3, 2024, to discuss these findings and their implications for regulatory submissions, including a New Drug Application expected in Q3 2024.
CYTK
$61.275+Infinity%1D
Analyst Views on CYTK
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 81.50 USD with a low forecast of 61.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 81.50 USD with a low forecast of 61.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
2 Hold
0 Sell
Strong Buy
Current: 62.020
Low
61.00
Averages
81.50
High
120.00
Current: 62.020
Low
61.00
Averages
81.50
High
120.00
RBC Capital
Outperform
maintain
$82 -> $87
2025-11-11
Reason
RBC Capital
Price Target
$82 -> $87
2025-11-11
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Cytokinetics to $87 from $82 and keeps an Outperform rating on the shares ahead of the company's "highly anticipated" launch of aficamten in 2026. The firm is updating its modeling assumptions on opex and revenues to better reflect what early U.S. launch dynamics in 2026 could look like following the December 2025 PDUFA, anchoring to historical competitor data, the analyst tells investors in a research note.
BofA
Jason Zemansky
Neutral
maintain
$62 -> $63
2025-11-06
Reason
BofA
Jason Zemansky
Price Target
$62 -> $63
2025-11-06
maintain
Neutral
Reason
BofA analyst Jason Zemansky raised the firm's price target on Cytokinetics to $63 from $62 and keeps a Neutral rating on the shares. The Q3 report and call were "uneventful" and unlikely to impact the thesis much, says the analyst, who cites adjusted operating expense projections, offset by the change in net cash, for the firm's price target increase.
JPMorgan
Overweight
maintain
$55 -> $70
2025-11-03
Reason
JPMorgan
Price Target
$55 -> $70
2025-11-03
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Cytokinetics to $70 from $55 and keeps an Overweight rating on the shares. The firm upped the price target after revisiting its epidemiology and diagnosis rate assumptions for obstructive and nonobstructive hypertrophic cardiomyopathy. Diagnosis trends indicate nonobstructive hypertrophic cardiomyopathy is growing at a faster rate than obstructive and could account for up to half of the total HCM market over time, the analyst tells investors in a research note.
BofA
Neutral
maintain
$56 -> $62
2025-10-21
Reason
BofA
Price Target
$56 -> $62
2025-10-21
maintain
Neutral
Reason
BofA raised the firm's price target on Cytokinetics to $62 from $56 and keeps a Neutral rating on the shares. After incorporating the latest feedback from key opinion leaders, the firm is "modestly" increasing its aficamten forecasts, the analyst tells investors.
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
